GLP1-SMG

Description

GLP1-SMG is APEX 100’s research-grade incretin-pathway analog—a 31-amino acid synthetic peptide engineered for a pharmacokinetic profile with extended activity. Its C18 fatty acid chain, conjugated at position 26 via a linker, enables non-covalent albumin binding that dramatically extends the compound’s half-life in preclinical models compared to the native peptide. In published Phase III investigative research, this compound has generated among the largest and most diverse outcome datasets of any peptide in its class, with peer-reviewed literature spanning cardiovascular events, weight endpoints, renal function, and neurological signals.

This breadth of published research makes it an essential reference compound for incretin-biology studies. APEX 100 sources GLP1-SMG to ≥99% HPLC purity with independent mass spectrometry confirmation of molecular identity. A current Certificate of Analysis is on file.

The lyophilized format is stable at -20°C and reconstitutes readily in bacteriostatic or sterile water.

For research and laboratory use only. Not for human consumption.